Published June 14, 2025 | Version v1
Journal article Open

Study of anticholinesterase properties of loratadine and desloratadine

Description

Given that antihistamines are among the most commonly used drugs among different age groups, availability and low cost of drugs, it is important to have complete information about their pharmacological profile and pleiotropic effects. The identification of new pharmacological properties of antihistamines may help to expand the indications for their use, improve treatment efficacy and reduce the risk of adverse reactions associated with polypharmacy. The aim of the work is to investigate and compare the effect of loratadine and desloratadine on the activity of the human serum butyrylcholinesterases enzyme. Materials and methods. The activity of butyrylcholinesterase and the effect of the antihistamine active pharmaceutical ingredients loratadine and desloratadine on this enzyme were determined ex vivo spectrophotometrically at a wavelength of 405 nm using the modified Ellman method. Experimental data processing included the calculation of steady-state velocities and kinetic parameters of inhibition and was performed according to standard methods. The kinetic characteristics of the studied process were analyzed and visualized in the SigmaPlot 14.0 software package. Results. It was found that both loratadine and desloratadine are dose-dependent inhibitors of butyrylcholinesterase. The both antihistamines inhibit butyrylcholinesterase by a mixed (partial) mechanism. The value of the enzyme inhibition constant (Ki) for loratadine is 10.15 ± 1.20 μM, and for desloratadine – 11.50 ± 1.30 μM. It was established that for loratadine the concentration required to achieve 50% inhibition of butyrylcholinesterase is IC50 = 117.78 ± 10.01 μM, and for desloratadine – 131.40 ± 13.03 μM. Conclusions. Given that human serum butyrylcholinesterase is involved in the metabolism of a number of drugs, including muscle relaxants and local anesthetics of the ether type, which causes their rapid inactivation and short-term effect, the inhibitory activity of loratadine and desloratadine against this enzyme is important for modifying the pharmacokinetic parameters of these compounds. The data obtained can serve as a basis for further studies aimed at studying the rate of decomposition of muscle relaxants and local anesthetic compounds by butyrylcholinesterase when used in combination with loratadine or desloratadine.

Files

smishkoFIN.pdf

Files (491.4 kB)

Name Size Download all
md5:ffa8275f113098e6dd54138db9780c47
491.4 kB Preview Download

Additional details

References

  • 1. Zhang L, Akdis CA. Environmental exposures drive the development of allergic diseases. Allergy. 2024;79(5):1081–1084. https://doi.org/10.1111/all.16112
  • 2. Wang J, Zhou Y, Zhang H, et al. Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduction and Targeted Therapy. 2023;8(1):138. https://doi.org/10.1038/s41392-023-01344-4
  • 3. Linton S, Hossenbaccus L, Ellis AK. Evidence-based use of antihistamines for treatment of allergic conditions. Annals of Allergy, Asthma & Immunology. 2023;131(4):412–420. https://doi.org/10.1016/j.anai.2023.07.019
  • 4. Trybus E, Trybus W. H1 antihistamines—Promising candidates for repurposing in the context of the development of new therapeutic approaches to cancer treatment. Cancers. 2024;16(24):4253. https://doi.org/10.3390/cancers16244253
  • 5. Ayaz M, Anwar F, Saleem U, et al. Parkinsonism Attenuation by Antihistamines via Downregulating the Oxidative Stress, Histamine, and Inflammation. ACS Omega. 2022;7(17):14772-14783. https://doi.org/10.1021/acsomega.2c00145
  • 6. Tandra G, Yoone A, Mathew R, et al. Literature-based discovery predicts antihistamines are a promising repurposed adjuvant therapy for Parkinson's disease. International Journal of Molecular Sciences. 2023;24(15):12339. https://doi.org/10.3390/ijms241512339
  • 7. Travi BL, Ferrer M. Current status of antihistamine drugs repurposing for infectious diseases. Medicine in Drug Discovery. 2022;15:100140. https://doi.org/10.1016/j.medidd.2022.100140
  • 8. Smishko R, Lyzhniuk V. Study of the range of antihistamines in the pharmaceutical market of Ukraine. Health & Education. 2024;(3):129–137. https://doi.org/10.32782/health-2024.3.15
  • 9. Terali K, Dalmizrak O, Uzairu S, Ozer N. New insights into the interaction between mammalian butyrylcholinesterase and amitriptyline: A combined experimental and computational approach. Turkish Journal of Biochemistry. 2019;44(1):55–61. https://doi.org/10.1515/tjb-2018-0063
  • 10. Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacology & Therapeutics. 2015;148:34–46. https://doi.org/10.1016/j.pharmthera.2014.11.011
  • 11. Li B, Sedlacek M, Manoharan I, et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochemical Pharmacology. 2005;70(11):1673–1684. https://doi.org/10.1016/j.bcp.2005.09.002
  • 12. Zhan CG, Zheng F, Landry DW. Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase. Journal of the American Chemical Society. 2003;125(9):2462–2474. https://doi.org/10.1021/ja020850
  • 13. Li S, Li AJ, Travers J, et al. Identification of compounds for butyrylcholinesterase inhibition. SLAS Discovery. 2021;26(10):1355–1364. https://doi.org/10.1177/24725552211030897
  • 14. Jońca J, Żuk M, Wasąg B, et al. New insights into butyrylcholinesterase activity assay: Serum dilution factor as a crucial parameter. PLOS ONE. 2015;10(10):e0139480. https://doi.org/10.1371/journal.pone.0139480
  • 15. Li Q, Yang H, Chen Y, Sun H. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. European Journal of Medicinal Chemistry. 2017;132:294–309. https://doi.org/10.1016/j.ejmech.2017.03.062
  • 16. Darvesh S. Butyrylcholinesterase as a diagnostic and therapeutic target for Alzheimer's disease. Current Alzheimer Research. 2016;13(10):1173–1177. https://doi.org/10.2174/1567205013666160404120542
  • 17. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Annals of Neurology. 1997;42(6):909–918. https://doi.org/10.1002/ana.410420613
  • 18. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology. 1961;7(2):88–95. https://doi.org/10.1016/0006-2952(61)90145-9
  • 19. Matvieieva N, Bessarabov V, Khainakova O, et al. Cichorium intybus L. "hairy" roots as a rich source of antioxidants and anti-inflammatory compounds. Heliyon. 2023;9(3):e14516. https://doi.org/10.1016/j.heliyon.2023.e14516
  • 20. Wolff SC, Brubaker K, Navratil T, et al. Anticholinergic effects of antihistamine drugs used in the clinic. Journal of Allergy and Clinical Immunology. 2007;119(1):153.
  • 21. Smishko RO, Strashnyi VV, Lisovyi VM, et al. Study of the influence of loratadine and desloratadine on 15-lipo xygenase activity. Technologies and Engineering. 2023;(4):96–103. https://doi.org/10.30857/2786-5371.2023.4.9 .
  • 22. Udovytskyi VV, Smishko RO, Lyzhniuk VV, et al. Study of the effect of antihistamine active pharmaceutical ingredients on the rate of dopamine oxidation in vitro. Farmatsevtychnyi Zhurnal. 2024;(5):86–96. https://doi.org/10.32352/0367-3057.5.24.07 .